Ideaya Biosciences Inc
General ticker "IDYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.3B
Ideaya Biosciences Inc does not follow the US Stock Market performance with the rate: -14.4%.
Estimated limits based on current volatility of 3.4%: low 24.45$, high 26.18$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [24.13$, 47.24$]
- 2024-12-30 to 2025-12-30 estimated range: [18.78$, 38.81$]
Financial Metrics affecting the IDYA estimates:
- Negative: Non-GAAP EPS, $ of -1.97 <= 0.10
- Negative: Operating profit margin, % of -85.18 <= 1.03
- Negative: Operating cash flow per share per price, % of -5.77 <= 2.35
- Positive: -3.48 < Investing cash flow per share, $ of -2.75
- Negative: negative Net income
- Negative: -0.39 < Industry inventory ratio change (median), % of 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term IDYA quotes
Long-term IDYA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $27.94MM | $50.93MM | $23.39MM |
| Operating Expenses | $78.21MM | $113.43MM | $157.81MM |
| Operating Income | $-50.27MM | $-62.50MM | $-134.43MM |
| Non-Operating Income | $0.51MM | $3.85MM | $21.47MM |
| R&D Expense | $58.16MM | $89.54MM | $129.51MM |
| Income(Loss) | $-49.76MM | $-58.66MM | $-112.96MM |
| Profit(Loss) | $-49.76MM | $-58.66MM | $-112.96MM |
| Stockholders Equity | $301.51MM | $349.45MM | $621.09MM |
| Inventory | $121.29MM | $8.32MM | $0.00MM |
| Assets | $381.35MM | $387.97MM | $649.32MM |
| Operating Cash Flow | $-55.78MM | $-87.17MM | $-115.22MM |
| Capital expenditure | $2.64MM | $3.44MM | $2.37MM |
| Investing Cash Flow | $-69.67MM | $-33.40MM | $-158.46MM |
| Financing Cash Flow | $145.45MM | $97.17MM | $362.72MM |
| Earnings Per Share* | $-1.35 | $-1.32 | $-1.96 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.